

2022 ACCP/ASHP BCOP Clinical Sessions:

Financial Disclosures

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speaker's bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identify and resolve conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Dr. Cuellar serves on the Speaker's Bureau for Seagen and Genentech.
- Dr. Dane has received honoraria from Janssen Pharmaceuticals for work developing clinical resources for extended VTE prophylaxis, Sanofi Genzyme for serving as a reviewer for Pharmacy Times Continuing Education, and from Bristol Myers Squibb for development activities for Pharmacy Times Continuing Education.
- Dr. DeRemer serves on a Scientific Advisory Board for MetasTX and on the Advisory Board-Immunotherapy for BMS.

None of the other planners for this activity have relevant financial relationships with ineligible companies to disclose.

All relevant financial relationships disclosed above have been mitigated.